Patients with plasmocytic myeloma have gained access to first-line treatment with daratumumab in the DRd regimen (in combination with lenalidomide and dexamethasone). Patients and their physicians have been waiting for this reimbursement decision.
As of January 1, the plasmocytic myeloma drug program included daratumumab therapy in the first-line treatment regimen dRDd for patients ineligible for autologous hematopoietic stem cell transplantation. This is the regimen recommended by Polish and international guidelines. Prof. Krzysztof Giannopoulos of the Department of Experimental Hematooncology at the Medical University of Lublin is pleased with the decision.
- This was one of the reimbursement white spots. Daratumumab in the daraVTD regimen was available for transplant-eligible patients, and in the DVd and DR...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
